ArticleCureus2025
Protein Kinase D1 (PRKD1) as a Diagnostic, Prognostic, and Immunomodulatory Biomarker in Human Cancers.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimProtein kinase D1 (PRKD1), a serine/threonine kinase, regulates cellular processes such as proliferation, apoptosis, migration, and immune responses. Depending on the tumor context, PRKD1 exhibits either oncogenic or tumor-suppressive functions. This study aimed to delineate the role of PRKD1 in cancer progression and assess its diagnostic and prognostic potential across multiple cancer types. MATERIALS AND
methodsWe analyzed PRKD1 expression using Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), and University of ALabama at Birmingham CANcer data analysis Portal (UALCAN) databases, and assessed its prognostic significance via the Kaplan-Meier plotter. Mutation profiles were examined using cBioPortal, while gene-gene and protein-protein interactions were evaluated through GeneMANIA and STRING, respectively. Pathway enrichment was performed using Enrichr. Findings were validated using three GEO datasets: GSE24152, GSE15641, and GSE110224.
resultsPRKD1 expression was significantly downregulated in bladder urothelial carcinoma (BLCA), kidney chromophobe (KICH), and rectum adenocarcinoma (READ) (all p < 0.001). Expression levels varied significantly with clinical parameters, including age, gender, race, and tumor stage. Immune infiltration analysis revealed significant associations between PRKD1 expression and immune cell subsets, namely, B cells, CD4⁺ T cells, macrophages, neutrophils, and dendritic cells in thyroid carcinoma (THCA), stomach adenocarcinoma (STAD), liver hepatocellular carcinoma (LIHC), and kidney renal clear cell carcinoma (KIRC). A notable inverse correlation was observed between PRKD1 and CD8⁺ T cell levels in THCA (p > 0.05). Survival analysis demonstrated that low PRKD1 expression correlated with improved prognosis in STAD, THCA, and LIHC, whereas high expression was favorable in KIRC (p = 0.001). Promoter methylation of PRKD1 was significantly increased in KICH and READ and decreased in BLCA (all p < 0.001), suggesting epigenetic regulation underlies its differential expression.
conclusionPRKD1 serves as a potential diagnostic biomarker in BLCA, KICH, and READ, and as a prognostic indicator in STAD, THCA, LIHC, and KIRC. Its expression is modulated by epigenetic mechanisms and correlates with immune cell infiltration, underscoring its relevance in tumor immunobiology and potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.